These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

857 related articles for article (PubMed ID: 22112477)

  • 1. Central nervous system.
    Adamson DC; Rasheed BA; McLendon RE; Bigner DD
    Cancer Biomark; 2010; 9(1-6):193-210. PubMed ID: 22112477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic and prognostic molecular markers in common adult gliomas.
    Rivera AL; Pelloski CE
    Expert Rev Mol Diagn; 2010 Jul; 10(5):637-49. PubMed ID: 20629512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fas (Apo-1, CD95) receptor expression in childhood astrocytomas. Is it a marker of the major apoptotic pathway or a signaling receptor for immune escape of neoplastic cells?
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    In Vivo; 1999; 13(4):357-73. PubMed ID: 10586378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond grade: molecular pathology of malignant gliomas.
    Sulman EP; Guerrero M; Aldape K
    Semin Radiat Oncol; 2009 Jul; 19(3):142-9. PubMed ID: 19464628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Histological and molecular classification of gliomas].
    Figarella-Branger D; Colin C; Coulibaly B; Quilichini B; Maues De Paula A; Fernandez C; Bouvier C
    Rev Neurol (Paris); 2008; 164(6-7):505-15. PubMed ID: 18565348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
    Lunsford LD; Flickinger JC; Larson D
    Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated molecular analysis suggests a three-class model for low-grade gliomas: a proof-of-concept study.
    Marko NF; Prayson RA; Barnett GH; Weil RJ
    Genomics; 2010 Jan; 95(1):16-24. PubMed ID: 19835948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver grafts from donors with central nervous system tumors: a single-center perspective.
    Kashyap R; Ryan C; Sharma R; Maloo MK; Safadjou S; Graham M; Tretheway D; Jain A; Orloff M
    Liver Transpl; 2009 Oct; 15(10):1204-8. PubMed ID: 19790151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma.
    Leins A; Riva P; Lindstedt R; Davidoff MS; Mehraein P; Weis S
    Cancer; 2003 Dec; 98(11):2430-9. PubMed ID: 14635078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nogo-a expression in glial CNS tumors: a tool to differentiate between oligodendrogliomas and other gliomas?
    Kuhlmann T; Gutenberg A; Schulten HJ; Paulus W; Rohde V; Bruck W
    Am J Surg Pathol; 2008 Oct; 32(10):1444-53. PubMed ID: 18685489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetics, prognosis and therapy of central nervous system tumors.
    Watkins D; Rouleau GA
    Cancer Detect Prev; 1994; 18(2):139-44. PubMed ID: 8025896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prostate stem cell antigen represents a novel glioma-associated antigen.
    Geiger KD; Hendruschk S; Rieber EP; Morgenroth A; Weigle B; Juratli T; Senner V; Schackert G; Temme A
    Oncol Rep; 2011 Jul; 26(1):13-21. PubMed ID: 21503583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropathological and molecular aspects of low-grade and high-grade gliomas.
    Michotte A; Neyns B; Chaskis C; Sadones J; In 't Veld P
    Acta Neurol Belg; 2004 Dec; 104(4):148-53. PubMed ID: 15742604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular biomarkers in pediatric glial tumors: a needed wind of change.
    Fontebasso AM; Bechet D; Jabado N
    Curr Opin Oncol; 2013 Nov; 25(6):665-73. PubMed ID: 24097106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensory and motor deficits of central nervous system origin.
    Aravabhumi S; Izzo KL
    Clin Podiatr Med Surg; 1989 Oct; 6(4):707-43. PubMed ID: 2680039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of alpha4 chain-containing laminins in human glial tumors identified by gene microarray analysis.
    Ljubimova JY; Lakhter AJ; Loksh A; Yong WH; Riedinger MS; Miner JH; Sorokin LM; Ljubimov AV; Black KL
    Cancer Res; 2001 Jul; 61(14):5601-10. PubMed ID: 11454714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer stem cells and malignant gliomas. From pathophysiology to targeted molecular therapy.
    Florian IS; Tomuleasa C; Soritau O; Timis T; Ioani H; Irimie A; Kacso G
    J BUON; 2011; 16(1):16-23. PubMed ID: 21674845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort.
    Pollack IF; Finkelstein SD; Burnham J; Holmes EJ; Hamilton RL; Yates AJ; Finlay JL; Sposto R;
    Cancer Res; 2001 Oct; 61(20):7404-7. PubMed ID: 11606370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor XIIIa-immunoreactivity in tumors of the central nervous system.
    Probst-Cousin S; Rickert CH; Gullotta F
    Clin Neuropathol; 1998; 17(2):79-84. PubMed ID: 9561329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spreading and migration of human glioma and rat C6 cells on central nervous system myelin in vitro is correlated with tumor malignancy and involves a metalloproteolytic activity.
    Amberger VR; Hensel T; Ogata N; Schwab ME
    Cancer Res; 1998 Jan; 58(1):149-58. PubMed ID: 9426071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.